Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188203 | 0.83 | MGLL (0.50) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL4287508 | 0.79 | CA1 (0.56) | AGTR2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29175644 | 0.75 | S1PR5 (0.64) | MEN1KMT2AALDH1A1SIGMAR1KDM4E | |
| SCHEMBL29175611 | 0.75 | S1PR5 (0.64) | MEN1KMT2AALDH1A1SIGMAR1KDM4E | |
| SCHEMBL29175613 | 0.75 | S1PR5 (0.64) | MEN1KMT2AALDH1A1SIGMAR1KDM4E | |
| SCHEMBL5058789 | 0.74 | HPGD (0.53) | KMT2ALMNAHPGDGPR183POLB | |
| SCHEMBL3617972 | 0.74 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL15148145 | 0.72 | AGTR2 (1.00) | AGTR2 | |
| SCHEMBL15152408 | 0.72 | AGTR2 (1.00) | AGTR2 | |
| SCHEMBL14917669 | 0.72 | AGTR2 (0.62) | AGTR2MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146574-A1 | Heterocycle Substituted Carboxylic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2008-06-19 | — | — | US | disclosed |
| US-7329680-B2 | Heterocycle substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1844043-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS FOR THE TREATMENT OF DIABETES | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060122222-A1 | Heterocycle substituted carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2006055708-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS FOR THE TREATMENT OF DIABETES | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1628970-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes of Pharmaceutical Discovery, LLC (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050004114-A1 | Heterocycle substituted carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | disclosed |
| WO-2004099192-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004114-A1 | Heterocycle substituted carboxylic acids | PTPRC, PTPRS, PTPRJ | AGTR2 1804/4885MEN1 2174/4885KMT2A 2597/4885 |
| US-20080146574-A1 | Heterocycle Substituted Carboxylic Acids | PTPRC, PTPRS, PTPRJ | AGTR2 1804/4885MEN1 2174/4885KMT2A 2597/4885 |
| US-20060122222-A1 | Heterocycle substituted carboxylic acids | PTPRC, PTPRS, PTPRJ | AGTR2 1804/4885MEN1 2174/4885KMT2A 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.